Showing results (61-70 of 176) with videos related to

Sort By:
Pageof 18
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 5, 2002
Relapsed, poor-prognosis ovarian cancer, individualized, interdisciplinary treatment approach, and quality of life: a case reportCatharina C Wenzel, Manuela P Schmidinger, Gottfried J Locker, et al.
Anesthesiology|May 1, 1997
Bronchoscopy via a redesigned Combitube in the esophageal position. A clinical evaluationP Krafft, M Röggla, P Fridrich, et al.
Human Pathology|May 1, 1998
Clonal and morphological variation in a posttransplant lymphoproliferative disorder: evolution from clonal T-cell to clonal B-cell predominanceB P Nelson, J Locker, M A Nalesnik, et al.
Life Sciences|January 1, 1996
9-cis retinoic acid is a direct hepatocyte mitogen in ratsT Ohmura, G L Columbano, A Columbano, et al.
Leukemia & Lymphoma|May 9, 2001
Decrease of circulating hematopoietic progenitor cells During interleukin-2 treatment is associated with an increase of vascular cell adhesion molecule-1, a critical molecule for progenitor cell adhesionG J Locker, B Stoiser, H Losert, et al.
Medizinische Klinik, Intensivmedizin Und Notfallmedizin|March 12, 2014
[Long-term use of an endovascular temperature catheter]D Krizanac, A Bojic, W Rabitsch, et al.
Cancer Research|March 1, 1997
Induction of cellular DNA synthesis in the pancreas and kidneys of rats by peroxisome proliferators, 9-cis retinoic acid, and 3,3',5-triiodo-L-thyronineT Ohmura, S L Katyal, J Locker, et al.
Wiener Klinische Wochenschrift|December 31, 2002
Endothelial cell activation and blood coagulation in critically ill patients with lung injuryCatharina Wenzel, Julia Kofler, Gottfried J Locker, et al.
Cancer|November 1, 1993
Lymphoma resembling Hodgkin disease after posttransplant lymphoproliferative disorder in a liver transplant recipientM A Nalesnik, P Randhawa, A J Demetris, et al.
Wiener Klinische Wochenschrift|December 10, 1999
[Clinical phase II-evaluation of neoadjuvant, cytostatic combination chemotherapy with docetaxel and epidoxorubicin in female breast cancer patients (T1-4, N0-2, M0)]C Wenzel, M Schmidinger, G J Locker, et al.
Pageof 18